SA26 Win Ratio Analyses of Multiple Endpoints in Rare Disease Trials: A Case-Study Based on a Trial of Avaglucosidase Alfa in Late-Onset Pompe Disease (LOPD)
Dec 1, 2022, 00:00
10.1016/j.jval.2022.09.2420
https://www.valueinhealthjournal.com/article/S1098-3015(22)04625-3/fulltext
Title :
SA26 Win Ratio Analyses of Multiple Endpoints in Rare Disease Trials: A Case-Study Based on a Trial of Avaglucosidase Alfa in Late-Onset Pompe Disease (LOPD)
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(22)04625-3&doi=10.1016/j.jval.2022.09.2420
First page :
Section Title :
Open access? :
No
Section Order :
11980